Logo

American Heart Association

  88
  0


Final ID: MP886

Changes in Management of Acute Aortic Syndrome with Vascular Medicine Involvement in a Multidisciplinary Aortic Team

Abstract Body (Do not enter title and authors here): Background: Recent AHA and ESC guidelines endorse multidisciplinary management of acute aortic syndromes (AAS), but the impact of including non-surgical cardiovascular specialists remains unexplored. In 2016, Beth Israel Deaconess Medical Center launched a multidisciplinary aortic center that includes vascular medicine (VM) consultation at the discretion of surgical teams.

Objective: To evaluate inpatient and post-discharge outcomes associated with VM consultation in patients with AAS.

Methods: We conducted a single-center retrospective study of 364 patients admitted with AAS between October 2010 and December 2023. Patients were stratified by VM consultation: VM+ (n=195) vs. VM− (n=169). Clinical characteristics, inpatient outcomes, discharge metrics, and follow-up data were compared between groups.

Results: VM+ patients were slightly older (68.0±15.3 vs. 65.6±14.1 years), more often female (47.2% vs. 42.0%), and had more former/current smokers (58.5% vs. 49.7%). Dissection was more common in the VM− group (92.3% vs. 80.5%), while mixed-type and intramural hematomas were more frequent in the VM+ group. In-hospital survival was significantly higher in the VM+ group (96.4% vs. 87.6%, p=0.003), with consistently higher survival across subgroups and an independent association with greater odds of survival (adjusted OR 3.13, 95% CI 1.14–8.60, p=0.027). At discharge, VM+ patients had lower systolic blood pressure (114±14.8 vs. 120±18.5 mmHg, p=0.003), lower heart rate (68.8±12.1 vs. 74.9±11.6 bpm, p<0.001), and more antihypertensive agents (2.64±1.38 vs. 1.81±1.09, p<0.001). Beta-blocker (94.7% vs. 88.5%, p=0.044) and ACEi/ARB (55.9% vs. 28.4%, p<0.001) use was also more common in VM+ patients. Length of stay (12.7±20.1 vs. 11.4±10.2 days, p=0.449) and 90-day readmission (28.2% vs. 31.8%, p=0.548) were similar. Follow-up at 12 months was more frequent in VM+ patients for vascular medicine (62.2% vs. 29.7%, p<0.001) and imaging (72.9% vs. 61.5%, p=0.034), while vascular surgery follow-up was more common in the VM− group (77.7% vs. 67.0%, p=0.038). Genetic evaluation within 24 months was also more frequent in VM+ patients (12.2% vs. 2.0%, p<0.001).

Conclusions: VM consultation in a multidisciplinary aortic team was associated with improved in-hospital survival, more intensive discharge medication management, and greater longitudinal follow-up. These findings support integrating VM specialists into team-based care for AAS.
  • Pettinato, Anthony  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Milioglou, Ioannis  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Diggins, Caroline  ( Harvard Medical School , Boston , Massachusetts , United States )
  • Krawisz, Anna  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Schmaier, Alec  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Secemsky, Eric  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Khabbaz, Kamal  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Schermerhorn, Marc  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Carroll, Brett  ( Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts , United States )
  • Author Disclosures:
    Anthony Pettinato: DO NOT have relevant financial relationships | Ioannis Milioglou: DO NOT have relevant financial relationships | Caroline Diggins: DO NOT have relevant financial relationships | Anna Krawisz: DO have relevant financial relationships ; Consultant:Medtronic:Past (completed) | Alec Schmaier: DO NOT have relevant financial relationships | Eric Secemsky: DO have relevant financial relationships ; Consultant:Abbott, Asahi, BD, Boston Scientific, Conavi, Cook, Cordis, Endovascular Engineering, Evident Vascular, Gore, InfraRedx , Medtronic, Philips, RapidAI, Rampart, R3, Shockwave , Siemens, Son i Vie, Teleflex, Terumo, Thrombolex, VentureMed , Zoll:Active (exists now) | Kamal Khabbaz: No Answer | Marc Schermerhorn: DO NOT have relevant financial relationships | Brett Carroll: DO have relevant financial relationships ; Consultant:Koya Medical:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Best of Aortic Aneurysm and Dissection Aortic disease - Clinical Science

Saturday, 11/08/2025 , 09:15AM - 10:15AM

Moderated Digital Poster Session

More abstracts on this topic:
A Therapeutic Vaccine Against Transforming Growth Factor-β Prevents Aortic Aneurysm Formation in a Mouse Model of Marfan Syndrome

Okamura Shun, Yagi Hiroki, Hayashi Hiroki, Ueda Tomomi, Shindo Akito, Kadowaki Hiroshi, Nakagami Hironori, Takeda Norihiko, Akazawa Hiroshi

Bioactive Oxylipins Predict Aortic Vascular Calcification Severity in Heart Failure with Preserved Ejection Fraction

Aradhyula Vaishnavi, Manandhar Sareeta, Maddipati Krishna Rao, Brewster Pamela, Smith Robert, Haller Steven, Kennedy David, Khouri Samer, Gupta Rajesh, Fares Anas, Vergis John, Dube Prabhatchandra, Sherafati Alborz, Kloster Alex, Khatib-shahidi Bella, Elzanaty Ahmed, Sajdeya Omar

You have to be authorized to contact abstract author. Please, Login
Not Available